$ADMA
ADMA BIOLOGICS, INC.

2022 Q3 Form 10-Q Financial Statement

#000114036122029116 Filed on August 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $41.09M $33.91M $29.10M
YoY Change 98.69% 90.15% 81.34%
Cost Of Revenue $31.43M $26.14M $25.44M
YoY Change 54.88% 38.78% 43.17%
Gross Profit $9.657M $7.769M $3.662M
YoY Change 2406.01% -875.36% -312.72%
Gross Profit Margin 23.5% 22.92% 12.58%
Selling, General & Admin $12.89M $11.97M $13.70M
YoY Change -7.06% 14.68% 36.53%
% of Gross Profit 133.52% 154.07% 374.1%
Research & Development $1.042M $873.4K $624.1K
YoY Change 35.22% -24.63% -36.81%
% of Gross Profit 10.79% 11.24% 17.04%
Depreciation & Amortization $1.700M $1.500M $1.400M
YoY Change 41.67% 36.36% 27.27%
% of Gross Profit 17.6% 19.31% 38.23%
Operating Expenses $18.97M $16.94M $18.48M
YoY Change 28.0% 16.22% 37.45%
Operating Profit -$9.317M -$9.175M -$14.82M
YoY Change -35.47% -41.12% -2.3%
Interest Expense $5.580M $4.573M $3.389M
YoY Change -269.39% 40.85% 6.05%
% of Operating Profit
Other Income/Expense, Net -$5.583M -$4.590M -$10.19M
YoY Change -30195.8% 38.09% 216.97%
Pretax Income -$14.90M -$13.76M -$25.01M
YoY Change -15.88% -27.19% 36.06%
Income Tax
% Of Pretax Income
Net Earnings -$14.90M -$13.76M -$25.01M
YoY Change -15.88% -27.19% 36.06%
Net Earnings / Revenue -36.26% -40.6% -85.93%
Basic Earnings Per Share -$0.08 -$0.07 -$0.13
Diluted Earnings Per Share -$0.08 -$0.07 -$0.13
COMMON SHARES
Basic Shares Outstanding 196.4M 196.4M 195.9M
Diluted Shares Outstanding 196.4M 196.4M 195.9M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $34.91M $52.42M $69.50M
YoY Change 1.44% 23.59% 12.1%
Cash & Equivalents $34.91M $52.42M $69.50M
Short-Term Investments
Other Short-Term Assets $5.372M $5.400M $5.519M
YoY Change -8.3% -5.3% -4.84%
Inventory $162.9M $146.1M $139.1M
Prepaid Expenses
Receivables $20.90M $18.88M $25.63M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $224.1M $222.8M $239.8M
YoY Change 28.21% 30.01% 35.25%
LONG-TERM ASSETS
Property, Plant & Equipment $56.95M $54.95M $53.22M
YoY Change 17.67% 18.21% 20.47%
Goodwill $3.530M $3.530M
YoY Change 0.84% 0.84%
Intangibles $1.192M $1.371M
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.459M $3.756M $2.826M
YoY Change 33.77% 48.65% 28.44%
Total Long-Term Assets $76.46M $74.16M $68.23M
YoY Change 19.74% 20.66% 16.9%
TOTAL ASSETS
Total Short-Term Assets $224.1M $222.8M $239.8M
Total Long-Term Assets $76.46M $74.16M $68.23M
Total Assets $300.6M $296.9M $308.0M
YoY Change 25.95% 27.54% 30.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $25.20M $11.39M $14.12M
YoY Change 45.8% 84.65% 15.7%
Accrued Expenses $16.99M $13.51M $14.22M
YoY Change 30.42% 25.91% 75.55%
Deferred Revenue $142.8K $142.8K
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $44.44M $28.07M $31.57M
YoY Change 37.43% 54.35% 48.9%
LONG-TERM LIABILITIES
Long-Term Debt $141.4M $139.8M $138.4M
YoY Change 49.81% 48.93% 48.2%
Other Long-Term Liabilities $362.2K $373.9K $11.11M
YoY Change -96.05% -95.92% 26374.11%
Total Long-Term Liabilities $362.2K $373.9K $149.5M
YoY Change -99.65% -99.64% 356227.68%
TOTAL LIABILITIES
Total Short-Term Liabilities $44.44M $28.07M $31.57M
Total Long-Term Liabilities $362.2K $373.9K $149.5M
Total Liabilities $200.2M $182.5M $181.1M
YoY Change 47.34% 50.58% 47.04%
SHAREHOLDERS EQUITY
Retained Earnings -$465.8M -$450.9M
YoY Change 19.35%
Common Stock $19.68K $19.64K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $100.4M $114.4M $126.9M
YoY Change
Total Liabilities & Shareholders Equity $300.6M $296.9M $308.0M
YoY Change 25.95% 27.54% 30.71%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$14.90M -$13.76M -$25.01M
YoY Change -15.88% -27.19% 36.06%
Depreciation, Depletion And Amortization $1.700M $1.500M $1.400M
YoY Change 41.67% 36.36% 27.27%
Cash From Operating Activities -$13.28M -$12.83M -$26.01M
YoY Change -0.95% -60.23% -21.72%
INVESTING ACTIVITIES
Capital Expenditures -$3.380M -$3.940M $2.842M
YoY Change 21.22% -11.99% 10.54%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$3.380M -$3.940M -$2.842M
YoY Change 21.22% -11.99% 10.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -843.8K -319.0K 47.27M
YoY Change -110.29% -101.86% 12.97%
NET CHANGE
Cash From Operating Activities -13.28M -12.83M -26.01M
Cash From Investing Activities -3.380M -3.940M -2.842M
Cash From Financing Activities -843.8K -319.0K 47.27M
Net Change In Cash -17.51M -17.09M 18.42M
YoY Change 118.91% -12.59% 204.67%
FREE CASH FLOW
Cash From Operating Activities -$13.28M -$12.83M -$26.01M
Capital Expenditures -$3.380M -$3.940M $2.842M
Free Cash Flow -$9.904M -$8.891M -$28.86M
YoY Change -6.77% -68.0% -19.4%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001368514
adma Number Of Remaining Plasma Collection Facilities Under Construction
NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction
2
CY2021Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1325994
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
63008100
CY2022Q2 us-gaap Liability Premium Deficiency Testing On Long Duration Contract Amount
LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount
344892
CY2021Q4 us-gaap Liability Premium Deficiency Testing On Long Duration Contract Amount
LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount
1189970
CY2021Q4 us-gaap Preferred Stock Capital Shares Reserved For Future Issuance
PreferredStockCapitalSharesReservedForFutureIssuance
10000000
CY2022Q2 us-gaap Preferred Stock Capital Shares Reserved For Future Issuance
PreferredStockCapitalSharesReservedForFutureIssuance
10000000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
196356232
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
195813817
CY2022Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
50523424
CY2022Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
53120344
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
1191047
CY2021Q2 us-gaap Share Based Compensation
ShareBasedCompensation
805189
us-gaap Share Based Compensation
ShareBasedCompensation
2832435
us-gaap Share Based Compensation
ShareBasedCompensation
1586586
adma Cost Of Product Revenue Excluding Amortization Expense
CostOfProductRevenueExcludingAmortizationExpense
51576660
CY2021 adma Number Of Fda Inspections
NumberOfFDAInspections
2
adma Plasma Supply Agreement Term
PlasmaSupplyAgreementTerm
P10Y
adma Plasma Purchased
PlasmaPurchased
22800000
adma Percentage Of Inventory Purchases
PercentageOfInventoryPurchases
0.66
adma Plasma Purchased
PlasmaPurchased
17500000
adma Percentage Of Inventory Purchases
PercentageOfInventoryPurchases
0.67
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2000000
adma Number Of Plasma Collection Facilities
NumberOfPlasmaCollectionFacilities
10
adma Number Of Fda Licensed Plasma Collection Facilities
NumberOfFDALicensedPlasmaCollectionFacilities
6
adma Number Of Additional Plasma Collections Centers In Operation And Collection Of Plasma
NumberOfAdditionalPlasmaCollectionsCentersInOperationAndCollectionOfPlasma
2
adma Number Of Remaining Plasma Collection Facilities Under Construction
NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction
2
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
33905007
CY2022Q2 adma Cost Of Product Revenue Excluding Amortization Expense
CostOfProductRevenueExcludingAmortizationExpense
26135614
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9174739
CY2022Q2 adma Interest And Other Nonoperating Income Expense
InterestAndOtherNonoperatingIncomeExpense
-4590167
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-13764906
CY2022Q2 us-gaap Assets
Assets
296932329
CY2022Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1724283
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17830590
CY2021Q2 adma Cost Of Product Revenue Excluding Amortization Expense
CostOfProductRevenueExcludingAmortizationExpense
18832624
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-15581232
CY2021Q2 adma Interest And Other Nonoperating Income Expense
InterestAndOtherNonoperatingIncomeExpense
-3324071
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-18905303
CY2021Q2 us-gaap Assets
Assets
232813792
us-gaap Operating Income Loss
OperatingIncomeLoss
-23989805
adma Interest And Other Nonoperating Income Expense
InterestAndOtherNonoperatingIncomeExpense
-8113017
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-6669941
us-gaap Net Income Loss
NetIncomeLoss
-38772763
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6782169
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3314500
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
33879208
adma Cost Of Product Revenue Excluding Amortization Expense
CostOfProductRevenueExcludingAmortizationExpense
36602746
us-gaap Operating Income Loss
OperatingIncomeLoss
-30745481
adma Interest And Other Nonoperating Income Expense
InterestAndOtherNonoperatingIncomeExpense
-6539763
us-gaap Net Income Loss
NetIncomeLoss
-37285244
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7046735
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2555622
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
33905007
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17830590
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
63008100
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
33879208
adma Operating Lease Incremental Borrowing Rate Percent
OperatingLeaseIncrementalBorrowingRatePercent
0.13
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
500000
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
400000
us-gaap Operating Lease Expense
OperatingLeaseExpense
900000
us-gaap Operating Lease Expense
OperatingLeaseExpense
600000
CY2022Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
400000
CY2021Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
600000
us-gaap Operating Lease Payments
OperatingLeasePayments
800000
us-gaap Operating Lease Payments
OperatingLeasePayments
800000
CY2022Q2 adma Operating And Financing Lease Liability
OperatingAndFinancingLeaseLiability
11500000
CY2021Q4 adma Operating And Financing Lease Liability
OperatingAndFinancingLeaseLiability
8100000
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y1M6D
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
945228
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2247057
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2223314
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2246432
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1996036
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
2040690
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
8238571
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
19937328
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
8486760
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
579661
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10870907
us-gaap Interest Paid Net
InterestPaidNet
5989332
us-gaap Interest Paid Net
InterestPaidNet
5534279
adma Equipment Acquired Reflected In Accounts Payable And Accrued Liabilities
EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities
1164319
adma Equipment Acquired Reflected In Accounts Payable And Accrued Liabilities
EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities
1005546
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3660890
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2844875
adma Warrants Issued In Connection With Notes Payable
WarrantsIssuedInConnectionWithNotesPayable
9569604
adma Warrants Issued In Connection With Notes Payable
WarrantsIssuedInConnectionWithNotesPayable
0
CY2022Q2 adma Working Capital
WorkingCapital
194700000
CY2022Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
52400000

Files In Submission

Name View Source Status
0001140361-22-029116-index-headers.html Edgar Link pending
0001140361-22-029116-index.html Edgar Link pending
0001140361-22-029116.txt Edgar Link pending
0001140361-22-029116-xbrl.zip Edgar Link pending
adma-20220630.xsd Edgar Link pending
brhc10040587_10q.htm Edgar Link pending
brhc10040587_ex31-1.htm Edgar Link pending
brhc10040587_ex31-2.htm Edgar Link pending
brhc10040587_ex32-1.htm Edgar Link pending
brhc10040587_ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
adma-20220630_cal.xml Edgar Link unprocessable
adma-20220630_pre.xml Edgar Link unprocessable
adma-20220630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
brhc10040587_10q_htm.xml Edgar Link completed
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
adma-20220630_def.xml Edgar Link unprocessable